Hanke, Benjamin, Juenger, Stephanie T., Kirches, Elmar, Waldt, Natalie, Schreiber, Jens, Lucke, Eva, Franke, Sabine, Sandalcioglu, I. Erol, Warnke, Jan-Peter, Meisel, Hans-Joerg, Prell, Julian, Scheller, Christian, Braunsdorf, Werner E. K., Preusser, Matthias, Schildhaus, Hans-Ulrich and Mawrin, Christian (2021). Frequency of actionable molecular drivers in lung cancer patients with precocious brain metastases. Clin. Neurol. Neurosurg., 208. AMSTERDAM: ELSEVIER. ISSN 1872-6968

Full text not available from this repository.

Abstract

Brain metastases frequently occur during the course of disease in patients suffering from lung cancer. Occasionally, neurological symptoms caused by brain metastases (BM) might represent the first sign of systemic tumor disease (so called precocious metastases), leading to the detection of the primary lung tumor. The biological basis of precocious BM is largely unknown, and treatment options are not well established for this subgroup of patients. Therefore, we retrospectively analyzed 33 patients (24 non-small cell lung cancer (NSCLC)), 9 small cell lung cancer (SCLC)) presenting with precocious BM focusing on molecular alterations potentially relevant for the tumor's biology and treatment. We found five FGFR1 amplifications (4 adenocarcinoma, 1 SCLC) among 31 analyzed patients (16.1%), eight MET amplifications among 30 analyzed tumors (7 NSCLC, 1 SCLC; 26.7%), three EGFR mutations within 33 patients (all adenocarcinomas, 9.1%), and five KRAS mutations among 32 patients (all adenocarcinomas; 15.6%). No ALK, ROS1 or RET gene rearrangements were detected. Our findings suggest that patients with precocious BM of lung cancer harbor EGFR mutations, MET amplifications or FGFR1 amplifications as potential targeted treatment options.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Hanke, BenjaminUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Juenger, Stephanie T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kirches, ElmarUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Waldt, NatalieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schreiber, JensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lucke, EvaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Franke, SabineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sandalcioglu, I. ErolUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Warnke, Jan-PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meisel, Hans-JoergUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Prell, JulianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheller, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Braunsdorf, Werner E. K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Preusser, MatthiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schildhaus, Hans-UlrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mawrin, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-595672
DOI: 10.1016/j.clineuro.2021.106841
Journal or Publication Title: Clin. Neurol. Neurosurg.
Volume: 208
Date: 2021
Publisher: ELSEVIER
Place of Publication: AMSTERDAM
ISSN: 1872-6968
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
IN-SITU HYBRIDIZATION; FGFR1 AMPLIFICATION; THERAPEUTIC-TARGET; CELL-CARCINOMA; EGFR; CHEMOTHERAPY; CRIZOTINIB; SURVIVAL; MET; REARRANGEMENTSMultiple languages
Clinical Neurology; SurgeryMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/59567

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item